Search CTL/CD8+ T-Cell Epitope Database

Found 61 matching records:

Displaying record number 1519

HXB2 Location	Gag(18-26) p17(18-26) DNA(841..867)	Gag Epitope Map
Author Location	p17(18-26 SF2)
Epitope	`KIRLRPGGK`	Epitope Alignment
Species (MHC/HLA)	human(A3)
Immunogen	HIV-1 infection
Experimental methods
Keywords	HAART, ART, acute/early infection

Notes

Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in individuals treated during chronic infection.
The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11 individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection (Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef.
Previously described and newly defined optimal epitopes were tested for CTL response.
Number of HLA-A3+ individuals that had a CTL response to this epitope broken down by group: 3/7 group 1, 0/4 group 2, and 2/2 group 3.

References

Altfeld2001b M. Altfeld, E. S. Rosenberg, R. Shankarappa, J. S. Mukherjee, F. M. Hecht, R. L. Eldridge, M. M. Addo, S. H. Poon, M. N. Phillips, G. K. Robbins, P. E. Sax, S. Boswell, J. O. Kahn, C. Brander, P. J. Goulder, J. A. Levy, J. I. Mullins, and B. D. Walker. Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection. J. Exp. Med., 193(2):169-80, 15 Jan 2001. URL: http://www.jem.org/cgi/content/full/193/2/169. PubMed ID: 11148221. Show all entries for this paper.

Displaying record number 1521

HXB2 Location	Gag(20-28) p17(20-28) DNA(847..873)	Gag Epitope Map
Author Location	p17(20-28 SF2)
Epitope	`RLRPGGKKK`	Epitope Alignment
Species (MHC/HLA)	human(A3)
Immunogen	HIV-1 infection
Experimental methods
Keywords	HAART, ART, acute/early infection

Notes

Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in individuals treated during chronic infection.
The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11 individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection (Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef.
Previously described and newly defined optimal epitopes were tested for CTL response.
Number of HLA-A3+ individuals that had a CTL response to this epitope broken down by group: 5/7 group 1, 2/4 group 2, and 2/2 group 3.

References

Displaying record number 1574

HXB2 Location	Gag(24-31) p17(24-31) DNA(859..882)	Gag Epitope Map
Author Location	p17(24-31 SF2)
Epitope	`GGKKKYKL`	Epitope Alignment
Species (MHC/HLA)	human(B8)
Immunogen	HIV-1 infection
Experimental methods
Keywords	HAART, ART, acute/early infection

Notes

Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in individuals treated during chronic infection.
The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11 individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection (Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef.
Previously described and newly defined optimal epitopes were tested for CTL response.
Number of HLA-B8+ individuals that had a CTL response to this epitope broken down by group: 0/3 group 1, 1/3 group 2, and 2/2 group 3.

References

Displaying record number 1538

HXB2 Location	Gag(28-36) p17(28-36) DNA(871..897)	Gag Epitope Map
Author Location	p17(28-36 SF2)
Epitope	`KYKLKHIVW`	Epitope Alignment
Species (MHC/HLA)	human(A24)
Immunogen	HIV-1 infection
Experimental methods
Keywords	HAART, ART, acute/early infection

Notes

Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in individuals treated during chronic infection.
The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11 individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection (Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef.
Previously described and newly defined optimal epitopes were tested for CTL response.
Number of HLA-A24+ individuals that had a CTL response to this epitope broken down by group: 0/0 group 1, 2/3 group 2, and 0/0 group 3.

References

Displaying record number 1565

HXB2 Location	Gag(36-44) p17(36-44) DNA(895..921)	Gag Epitope Map
Author Location	p17(36-44 SF2)
Epitope	`WASRELERF`	Epitope Alignment
Species (MHC/HLA)	human(B35)
Immunogen	HIV-1 infection
Experimental methods
Keywords	HAART, ART, acute/early infection

Notes

Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in individuals treated during chronic infection.
The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11 individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection (Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef.
Previously described and newly defined optimal epitopes were tested for CTL response.
Number of HLA-B35+ individuals that had a CTL response to this epitope broken down by group: 0/2 group 1, 0/2 group 2, and 1/1 group 3.

References

Displaying record number 1534

HXB2 Location	Gag(76-86) p17(76-86) DNA(1015..1047)	Gag Epitope Map
Author Location	p17(74-86 SF2)
Epitope	`RSLYNTVATLY`	Epitope Alignment
Species (MHC/HLA)	human(A30)
Immunogen	HIV-1 infection
Experimental methods
Keywords	HAART, ART, acute/early infection

Notes

Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in individuals treated during chronic infection.
The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11 individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection (Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef.
Previously described and newly defined optimal epitopes were tested for CTL response.
Number of HLA-A30+ individuals that had a CTL response to this epitope broken down by group: 0/1 group 1, 0/0 group 2, and 1/1 group 3.

References

Displaying record number 1579

HXB2 Location	Gag(77-85) p17(77-85) DNA(1018..1044)	Gag Epitope Map
Author Location	p17(77-85 SF2)
Epitope	`SLYNTVATL`	Epitope Alignment
Species (MHC/HLA)	human(A2)
Immunogen	HIV-1 infection
Experimental methods
Keywords	HAART, ART, acute/early infection

Notes

Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in individuals treated during chronic infection.
The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11 individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection (Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef.
Previously described and newly defined optimal epitopes were tested for CTL response.
Number of HLA-A2+ individuals that had a CTL response to this epitope broken down by group: 1/10 group 1, 2/6 group 2, and 2/4 group 3.

References

Displaying record number 1539

HXB2 Location	Gag(84-92) p17(84-92) DNA(1039..1065)	Gag Epitope Map
Author Location	p17(84-92 SF2)
Epitope	`TLYCVHQRI`	Epitope Alignment
Species (MHC/HLA)	human(A11)
Immunogen	HIV-1 infection
Experimental methods
Keywords	HAART, ART, acute/early infection

Notes

Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in individuals treated during chronic infection.
The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11 individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection (Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef.
Previously described and newly defined optimal epitopes were tested for CTL response.
Number of HLA-A11+ individuals that had a CTL response to this epitope broken down by group: 0/3 group 1, 0/0 group 2, and 1/2 group 3.

References

Displaying record number 1522

HXB2 Location	Gag(92-101) p17(92-101) DNA(1063..1092)	Gag Epitope Map
Author Location	p17(92-101 SF2)
Epitope	`IEIKDTKEAL`	Epitope Alignment
Species (MHC/HLA)	human(B60)
Immunogen	HIV-1 infection
Experimental methods
Keywords	HAART, ART, acute/early infection

Notes

Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in individuals treated during chronic infection.
The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11 individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection (Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef.
Previously described and newly defined optimal epitopes were tested for CTL response.
Number of HLA-B60+ individuals that had a CTL response to this epitope broken down by group: 0/2 group 1, 1/1 group 2, and 0/0 group 3.

References

Displaying record number 1564

HXB2 Location	Gag(124-132) p17(124-132) DNA(1159..1185)	Gag Epitope Map
Author Location	p17(124-132 SF2)
Epitope	`NSSKVSQNY`	Epitope Alignment
Species (MHC/HLA)	human(B35)
Immunogen	HIV-1 infection
Experimental methods
Keywords	HAART, ART, acute/early infection

Notes

Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in individuals treated during chronic infection.
The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11 individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection (Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef.
Previously described and newly defined optimal epitopes were tested for CTL response.
Number of HLA-B35+ individuals that had a CTL response to this epitope broken down by group: 0/2 group 1, 0/2 group 2, and 1/1 group 3.

References

Displaying record number 1537

HXB2 Location	Gag(145-155) p24(13-23) DNA(1222..1254)	Gag Epitope Map
Author Location	p24(145-155 SF2)
Epitope	`QAISPRTLNAV`	Epitope Alignment
Species (MHC/HLA)	human(A25)
Immunogen	HIV-1 infection
Experimental methods
Keywords	HAART, ART, acute/early infection

Notes

Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in individuals treated during chronic infection.
The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11 individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection (Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef.
Previously described and newly defined optimal epitopes were tested for CTL response.
Number of HLA-A25+ individuals that had a CTL response to this epitope broken down by group: 0/0 group 1, 0/2 group 2, and 1/3 group 3.

References

Displaying record number 1556

HXB2 Location	Gag(147-155) p24(15-23) DNA(1228..1254)	Gag Epitope Map
Author Location	p24(147-155 SF2)
Epitope	`ISPRTLNAW`	Epitope Alignment
Species (MHC/HLA)	human(B57)
Immunogen	HIV-1 infection
Experimental methods
Keywords	HAART, ART, acute/early infection

Notes

Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in individuals treated during chronic infection.
The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11 individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection (Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef.
Previously described and newly defined optimal epitopes were tested for CTL response.
Number of HLA-B57+ individuals that had a CTL response to this epitope broken down by group: 0/0 group 1, 0/0 group 2, and 2/2 group 3.

References

Displaying record number 1555

HXB2 Location	Gag(162-172) p24(30-40) DNA(1273..1305)	Gag Epitope Map
Author Location	p24(162-172 SF2)
Epitope	`KAFSPEVIPMF`	Epitope Alignment
Species (MHC/HLA)	human(B57)
Immunogen	HIV-1 infection
Experimental methods
Keywords	HAART, ART, acute/early infection

Notes

Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in individuals treated during chronic infection.
The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11 individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection (Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef.
Previously described and newly defined optimal epitopes were tested for CTL response.
Number of HLA-B57+ individuals that had a CTL response to this epitope broken down by group: 0/0 group 1, 0/0 group 2, and 2/2 group 3.

References

Displaying record number 1536

HXB2 Location	Gag(203-212) p24(71-80) DNA(1396..1425)	Gag Epitope Map
Author Location	p24(203-212 SF2)
Epitope	`ETINEEAAEW`	Epitope Alignment
Species (MHC/HLA)	human(A25)
Immunogen	HIV-1 infection
Experimental methods
Keywords	HAART, ART, acute/early infection

Notes

Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in individuals treated during chronic infection.
The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11 individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection (Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef.
Previously described and newly defined optimal epitopes were tested for CTL response.
Number of HLA-A25+ individuals that had a CTL response to this epitope broken down by group: 0/0 group 1, 0/2 group 2, and 1/3 group 3.

References

Displaying record number 1552

HXB2 Location	Gag(240-249) p24(108-117) DNA(1507..1536)	Gag Epitope Map
Author Location	p24(240-249 SF2)
Epitope	`TSTLQEQIGW`	Epitope Alignment
Species (MHC/HLA)	human(B58)
Immunogen	HIV-1 infection
Experimental methods
Keywords	HAART, ART, acute/early infection

Notes

Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in individuals treated during chronic infection.
The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11 individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection (Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef.
Previously described and newly defined optimal epitopes were tested for CTL response.
Number of HLA-B58+ individuals that had a CTL response to this epitope broken down by group: 0/0 group 1, 1/1 group 2, and 0/0 group 3.

References

Displaying record number 1563

HXB2 Location	Gag(254-262) p24(122-130) DNA(1549..1575)	Gag Epitope Map
Author Location	p24(254-262 SF2)
Epitope	`PPIPVGDIY`	Epitope Alignment
Species (MHC/HLA)	human(B35)
Immunogen	HIV-1 infection
Experimental methods
Keywords	HAART, ART, acute/early infection

Notes

Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in individuals treated during chronic infection.
The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11 individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection (Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef.
Previously described and newly defined optimal epitopes were tested for CTL response.
Number of HLA-B35+ individuals that had a CTL response to this epitope broken down by group: 0/2 group 1, 0/2 group 2, and 1/1 group 3.

References

Displaying record number 1575

HXB2 Location	Gag(259-267) p24(127-135) DNA(1564..1590)	Gag Epitope Map
Author Location	p24(259-267 SF2)
Epitope	`GEIYKRWII`	Epitope Alignment
Species (MHC/HLA)	human(B8)
Immunogen	HIV-1 infection
Experimental methods
Keywords	HAART, ART, acute/early infection

Notes

Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in individuals treated during chronic infection.
The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11 individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection (Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef.
Previously described and newly defined optimal epitopes were tested for CTL response.
Number of HLA-B8+ individuals that had a CTL response to this epitope broken down by group: 2/3 group 1, 2/3 group 2, and 2/2 group 3.

References

Displaying record number 1567

HXB2 Location	Gag(263-272) p24(131-140) DNA(1576..1605)	Gag Epitope Map
Author Location	p24(265-274 SF2)
Epitope	`KRWIILGLNK`	Epitope Alignment
Species (MHC/HLA)	human(B27)
Immunogen	HIV-1 infection
Experimental methods
Keywords	HAART, ART, acute/early infection

Notes

Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in individuals treated during chronic infection.
The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11 individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection (Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef.
Previously described and newly defined optimal epitopes were tested for CTL response.
Number of HLA-B27+ individuals that had a CTL response to this epitope broken down by group: 0/0 group 1, 0/0 group 2, and 1/1 group 3.

References

Displaying record number 1551

HXB2 Location	Gag(269-277) p24(137-145) DNA(1594..1620)	Gag Epitope Map
Author Location	p24(267-277 SF2)
Epitope	`GLNKIVRMY`	Epitope Alignment
Species (MHC/HLA)	human(B62)
Immunogen	HIV-1 infection
Experimental methods
Keywords	HAART, ART, acute/early infection

Notes

Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in individuals treated during chronic infection.
The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11 individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection (Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef.
Previously described and newly defined optimal epitopes were tested for CTL response.
Number of HLA-B62+ individuals that had a CTL response to this epitope broken down by group: 0/1 group 1, 0/1 group 2, and 1/1 group 3.

References

Displaying record number 1523

HXB2 Location	Gag(298-306) p24(166-174) DNA(1681..1707)	Gag Epitope Map
Author Location	p24(298-306 SF2)
Epitope	`DRFYKTLRA`	Epitope Alignment
Species (MHC/HLA)	human(B14)
Immunogen	HIV-1 infection
Experimental methods
Keywords	HAART, ART, acute/early infection

Notes

Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in individuals treated during chronic infection.
The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11 individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection (Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef.
Previously described and newly defined optimal epitopes were tested for CTL response.
Number of HLA-B14+ individuals that had a CTL response to this epitope broken down by group: 3/3 group 1, 1/2 group 2, and 0/0 group 3.

References

Displaying record number 1554

HXB2 Location	Gag(308-317) p24(176-185) DNA(1711..1740)	Gag Epitope Map
Author Location	p24(311-319 SF2)
Epitope	`QASKEVKNWV`	Epitope Alignment
Species (MHC/HLA)	human(B57)
Immunogen	HIV-1 infection
Experimental methods
Keywords	HAART, ART, acute/early infection

Notes

Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in individuals treated during chronic infection.
The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11 individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection (Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef.
Previously described and newly defined optimal epitopes were tested for CTL response.
Number of HLA-B57+ individuals that had a CTL response to this epitope broken down by group: 0/0 group 1, 0/0 group 2, and 1/2 group 3.

References

Displaying record number 1540

HXB2 Location	Gag(349-359) p24(217-227) DNA(1834..1866)	Gag Epitope Map
Author Location	p24(349-359 SF2)
Epitope	`ACQGVGGPGHK`	Epitope Alignment
Species (MHC/HLA)	human(A11)
Immunogen	HIV-1 infection
Experimental methods
Keywords	HAART, ART, acute/early infection

Notes

Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in individuals treated during chronic infection.
The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11 individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection (Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef.
Previously described and newly defined optimal epitopes were tested for CTL response.
Number of HLA-A11+ individuals that had a CTL response to this epitope broken down by group: 0/3 group 1, 0/0 group 2, and 2/2 group 3.

References

Displaying record number 1544

HXB2 Location	Gag(355-363) p24(223-231) DNA(1852..1878)	Gag Epitope Map
Author Location	p24(223-231 SF2)
Epitope	`GPGHKARVL`	Epitope Alignment
Species (MHC/HLA)	human(B7)
Immunogen	HIV-1 infection
Experimental methods
Keywords	HAART, ART, acute/early infection

Notes

Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in individuals treated during chronic infection.
The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11 individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection (Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef.
Previously described and newly defined optimal epitopes were tested for CTL response.
Number of HLA-B7+ individuals that had a CTL response to this epitope broken down by group: 1/4 group 1, 2/3 group 2, and 0/1 group 3.

References

Displaying record number 1576

HXB2 Location	Pol(173-181) RT(18-26) DNA(2601..2627)	Pol Epitope Map
Author Location	RT(185-193 SF2)
Epitope	`GPKVKQWPL`	Epitope Alignment
Species (MHC/HLA)	human(B8)
Immunogen	HIV-1 infection
Experimental methods
Keywords	HAART, ART, acute/early infection

Notes

Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in individuals treated during chronic infection.
The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11 individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection (Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef.
Previously described and newly defined optimal epitopes were tested for CTL response.
Number of HLA-B8+ individuals that had a CTL response to this epitope broken down by group: 0/3 group 1, 0/3 group 2, and 2/2 group 3.

References

Displaying record number 1562

HXB2 Location	Pol(262-270) RT(107-115) DNA(2868..2894)	Pol Epitope Map
Author Location	RT(262-270 SF2)
Epitope	`TVLDVGDAY`	Epitope Alignment
Species (MHC/HLA)	human(B35)
Immunogen	HIV-1 infection
Experimental methods
Keywords	HAART, ART, acute/early infection

Notes

Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in individuals treated during chronic infection.
The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11 individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection (Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef.
Previously described and newly defined optimal epitopes were tested for CTL response.
Number of HLA-B35+ individuals that had a CTL response to this epitope broken down by group: 1/2 group 1, 0/2 group 2, and 0/1 group 3.

References

Displaying record number 1561

HXB2 Location	Pol(273-282) RT(118-127) DNA(2901..2930)	Pol Epitope Map
Author Location	RT(273-282 SF2)
Epitope	`VPLDEDFRKY`	Epitope Alignment
Species (MHC/HLA)	human(B35)
Immunogen	HIV-1 infection
Experimental methods
Keywords	HAART, ART, acute/early infection

Notes

Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in individuals treated during chronic infection.
The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11 individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection (Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef.
Previously described and newly defined optimal epitopes were tested for CTL response.
Number of HLA-B35+ individuals that had a CTL response to this epitope broken down by group: 1/2 group 1, 0/2 group 2, and 1/1 group 3.

References

Displaying record number 1547

HXB2 Location	Pol(311-319) RT(156-164) DNA(3015..3041)	Pol Epitope Map
Author Location	RT(323-331 SF2)
Epitope	`SPAIFQSSM`	Epitope Alignment
Species (MHC/HLA)	human(B7)
Immunogen	HIV-1 infection
Experimental methods
Keywords	HAART, ART, acute/early infection

Notes

Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in individuals treated during chronic infection.
The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11 individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection (Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef.
Previously described and newly defined optimal epitopes were tested for CTL response.
Number of HLA-B7+ individuals that had a CTL response to this epitope broken down by group: 0/4 group 1, 0/3 group 2, and 1/1 group 3.

References

Displaying record number 1524

HXB2 Location	Pol(313-321) RT(158-166) DNA(3021..3047)	Pol Epitope Map
Author Location	RT(325-333 SF2)
Epitope	`AIFQSSMTK`	Epitope Alignment
Species (MHC/HLA)	human(A3)
Immunogen	HIV-1 infection
Experimental methods
Keywords	HAART, ART, acute/early infection

Notes

Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in individuals treated during chronic infection.
The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11 individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection (Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef.
Previously described and newly defined optimal epitopes were tested for CTL response.
Number of HLA-A3+ individuals that had a CTL response to this epitope broken down by group: 0/7 group 1, 0/4 group 2, and 1/2 group 3.

References

Displaying record number 1560

HXB2 Location	Pol(330-338) RT(175-183) DNA(3072..3098)	Pol Epitope Map
Author Location	RT(175-183 SF2)
Epitope	`NPDIVIYQY`	Epitope Alignment
Species (MHC/HLA)	human(B35)
Immunogen	HIV-1 infection
Experimental methods
Keywords	HAART, ART, acute/early infection

Notes

Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in individuals treated during chronic infection.
The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11 individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection (Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef.
Previously described and newly defined optimal epitopes were tested for CTL response.
Number of HLA-B35+ individuals that had a CTL response to this epitope broken down by group: 1/2 group 1, 0/2 group 2, and 1/1 group 3.

References

Displaying record number 1525

HXB2 Location	Pol(357-365) RT(202-210) DNA(3153..3179)	Pol Epitope Map
Author Location	RT( SF2)
Epitope	`IEELRQHLL`	Epitope Alignment
Species (MHC/HLA)	human(B60)
Immunogen	HIV-1 infection
Experimental methods
Keywords	HAART, ART, acute/early infection

Notes

Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in individuals treated during chronic infection.
The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11 individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection (Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef.
Previously described and newly defined optimal epitopes were tested for CTL response.
Number of HLA-B60+ individuals that had a CTL response to this epitope broken down by group: 0/2 group 1, 1/1 group 2, and 0/0 group 3.

References

Displaying record number 1520

HXB2 Location	Pol(464-472) RT(309-317) DNA(3474..3500)	Pol Epitope Map
Author Location	RT(476-484 SF2)
Epitope	`ILKEPVHGV`	Epitope Alignment
Species (MHC/HLA)	human(A2)
Immunogen	HIV-1 infection
Experimental methods
Keywords	HAART, ART, acute/early infection

Notes

Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in individuals treated during chronic infection.
The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11 individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection (Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef.
Previously described and newly defined optimal epitopes were tested for CTL response.
Number of HLA-A2+ individuals that had a CTL response to this epitope broken down by group: 1/10 group 1, 0/6 group 2, and 3/4 group 3.

References

Displaying record number 1541

HXB2 Location	Pol(496-505) RT(341-350) DNA(3570..3599)	Pol Epitope Map
Author Location	RT(508-517 SF2)
Epitope	`IYQEPFKNLK`	Epitope Alignment
Species (MHC/HLA)	human(A11)
Immunogen	HIV-1 infection
Experimental methods
Keywords	HAART, ART, acute/early infection

Notes

Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in individuals treated during chronic infection.
The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11 individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection (Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef.
Previously described and newly defined optimal epitopes were tested for CTL response.
Number of HLA-A11+ individuals that had a CTL response to this epitope broken down by group: 0/3 group 1, 0/0 group 2, and 1/2 group 3.

References

Displaying record number 1553

HXB2 Location	Pol(530-538) RT(375-383) DNA(3672..3698)	Pol Epitope Map
Author Location	RT(375-383 SF2)
Epitope	`ITTESIVIW`	Epitope Alignment
Species (MHC/HLA)	human(B57)
Immunogen	HIV-1 infection
Experimental methods
Keywords	HAART, ART, acute/early infection

Notes

Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in individuals treated during chronic infection.
The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11 individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection (Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef.
Previously described and newly defined optimal epitopes were tested for CTL response.
Number of HLA-B57+ individuals that had a CTL response to this epitope broken down by group: 0/0 group 1, 0/0 group 2, and 1/2 group 3.

References

Displaying record number 1533

HXB2 Location	Pol(547-556) RT(392-401) DNA(3723..3752)	Pol Epitope Map
Author Location	RT(559-568 SF2)
Epitope	`PIQKETWETW`	Epitope Alignment
Species (MHC/HLA)	human(A32)
Immunogen	HIV-1 infection
Experimental methods
Keywords	HAART, ART, acute/early infection

Notes

Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in individuals treated during chronic infection.
The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11 individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection (Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef.
Previously described and newly defined optimal epitopes were tested for CTL response.
Number of HLA-A32+ individuals that had a CTL response to this epitope broken down by group: 0/0 group 1, 1/1 group 2, and 0/0 group 3.

References

Displaying record number 1532

HXB2 Location	Vpr(59-67) DNA(5733..5759)	Vpr Epitope Map
Author Location	Vpr(59-67 SF2)
Epitope	`AIIRILQQL`	Epitope Alignment
Species (MHC/HLA)	human(A2)
Immunogen	HIV-1 infection
Experimental methods
Keywords	HAART, ART, acute/early infection

Notes

Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in individuals treated during chronic infection.
The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11 individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection (Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef.
Previously described and newly defined optimal epitopes were tested for CTL response.
Number of HLA-A2+ individuals that had a CTL response to this epitope broken down by group: 1/10 group 1, 0/6 group 2, and 0/4 group 3.

References

Displaying record number 1550

HXB2 Location	Rev(67-75) DNA(8501..8527)	Rev Epitope Map
Author Location	Rev(67-75 SF2)
Epitope	`SAEPVPLQL`	Epitope Alignment
Species (MHC/HLA)	human(Cw5)
Immunogen	HIV-1 infection
Experimental methods
Keywords	HAART, ART, acute/early infection

Notes

Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in individuals treated during chronic infection.
The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11 individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection (Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef.
Previously described and newly defined optimal epitopes were tested for CTL response.
Number of HLA-Cw5+ individuals that had a CTL response to this epitope broken down by group: 2/6 group 1, 0/1 group 2, and 0/2 group 3.

References

Displaying record number 1557

HXB2 Location	gp160(31-39) gp120(31-39) DNA(6315..6341)	gp160 Epitope Map
Author Location	gp120(30-38 SF2)
Epitope	`AENLWVTVY`	Epitope Alignment
Species (MHC/HLA)	human(B44)
Immunogen	HIV-1 infection
Experimental methods
Keywords	HAART, ART, acute/early infection

Notes

Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in individuals treated during chronic infection.
The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11 individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection (Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef.
Previously described and newly defined optimal epitopes were tested for CTL response.
Number of HLA-B44+ individuals that had a CTL response to this epitope broken down by group: 1/8 group 1, 2/3 group 2, and 3/4 group 3.

References

Displaying record number 1559

HXB2 Location	gp160(78-86) gp120(78-86) DNA(6456..6482)	gp160 Epitope Map
Author Location	gp120(77-85 SF2)
Epitope	`DPNPQEVVL`	Epitope Alignment
Species (MHC/HLA)	human(B35)
Immunogen	HIV-1 infection
Experimental methods
Keywords	HAART, ART, acute/early infection

Notes

Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in individuals treated during chronic infection.
The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11 individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection (Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef.
Previously described and newly defined optimal epitopes were tested for CTL response.
Number of HLA-B35+ individuals that had a CTL response to this epitope broken down by group: 1/2 group 1, 0/2 group 2, and 0/1 group 3.

References

Displaying record number 1535

HXB2 Location	gp160(209-217) gp120(209-217) DNA(6849..6875)	gp160 Epitope Map
Author Location	gp120(213-221 SF2)
Epitope	`SFEPIPIHY`	Epitope Alignment
Species (MHC/HLA)	human(A29)
Immunogen	HIV-1 infection
Experimental methods
Keywords	HAART, ART, acute/early infection

Notes

Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in individuals treated during chronic infection.
The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11 individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection (Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef.
Previously described and newly defined optimal epitopes were tested for CTL response.
Number of HLA-A29+ individuals that had a CTL response to this epitope broken down by group: 1/3 group 1, 0/0 group 2, and 0/0 group 3.

References

Displaying record number 1546

HXB2 Location	gp160(298-307) gp120(298-307) DNA(7116..7145)	gp160 Epitope Map
Author Location	gp120(303-312 SF2)
Epitope	`RPNNNTRKSI`	Epitope Alignment
Species (MHC/HLA)	human(B7)
Immunogen	HIV-1 infection
Experimental methods
Keywords	HAART, ART, acute/early infection

Notes

Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in individuals treated during chronic infection.
The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11 individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection (Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef.
Previously described and newly defined optimal epitopes were tested for CTL response.
Number of HLA-B7+ individuals that had a CTL response to this epitope broken down by group: 0/4 group 1, 1/3 group 2, and 1/1 group 3.

References

Displaying record number 1569

HXB2 Location	gp160(375-383) gp120(375-383) DNA(7347..7373)	gp160 Epitope Map
Author Location	gp120(375-383 SF2)
Epitope	`SFNCGGEFF`	Epitope Alignment
Species (MHC/HLA)	human(B15)
Immunogen	HIV-1 infection
Experimental methods
Keywords	HAART, ART, acute/early infection

Notes

Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in individuals treated during chronic infection.
The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11 individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection (Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef.
Previously described and newly defined optimal epitopes were tested for CTL response.
Number of HLA-B15+ individuals that had a CTL response to this epitope broken down by group: 0/0 group 1, 1/1 group 2, and 0/1 group 3.

References

Displaying record number 1526

HXB2 Location	gp160(584-592) gp41(73-81) DNA(7974..8000)	gp160 Epitope Map
Author Location	gp41(589-597 SF2)
Epitope	`ERYLKDQQL`	Epitope Alignment
Species (MHC/HLA)	human(B14)
Immunogen	HIV-1 infection
Experimental methods
Keywords	HAART, ART, acute/early infection

Notes

Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in individuals treated during chronic infection.
The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11 individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection (Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef.
Previously described and newly defined optimal epitopes were tested for CTL response.
Number of HLA-B14+ individuals that had a CTL response to this epitope broken down by group: 3/3 group 1, 1/2 group 2, and 0/0 group 3.

References

Displaying record number 1530

HXB2 Location	gp160(813-822) gp41(302-311) DNA(8661..8690)	gp160 Epitope Map
Author Location	gp41(77-85 SF2)
Epitope	`SLLNATDIAV`	Epitope Alignment
Species (MHC/HLA)	human(A2)
Immunogen	HIV-1 infection
Experimental methods
Keywords	HAART, ART, acute/early infection

Notes

Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in individuals treated during chronic infection.
The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11 individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection (Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef.
Previously described and newly defined optimal epitopes were tested for CTL response.
Number of HLA-A2+ individuals that had a CTL response to this epitope broken down by group: 1/10 group 1, 2/6 group 2, and 1/4 group 3.

References

Displaying record number 1548

HXB2 Location	gp160(822-832) gp41(311-321) DNA(8688..8720)	gp160 Epitope Map
Author Location	gp41( SF2)
Epitope	`VAEGTDRVIEI`	Epitope Alignment
Species (MHC/HLA)	human
Immunogen	HIV-1 infection
Experimental methods
Keywords	HAART, ART, acute/early infection

Notes

Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in individuals treated during chronic infection.
The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11 individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection (Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef.
Previously described and newly defined optimal epitopes were tested for CTL response.
Number of individuals that had a CTL response to this epitope (HLA presenting molecule uncertain) broken down by group: 0 group 1, 1 group 2, and 0 group 3.

References

Displaying record number 1545

HXB2 Location	gp160(843-851) gp41(332-340) DNA(8751..8777)	gp160 Epitope Map
Author Location	gp41(843-851 SF2)
Epitope	`IPRRIRQGL`	Epitope Alignment
Species (MHC/HLA)	human(B7)
Immunogen	HIV-1 infection
Experimental methods
Keywords	HAART, ART, acute/early infection

Notes

Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in individuals treated during chronic infection.
The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11 individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection (Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef.
Previously described and newly defined optimal epitopes were tested for CTL response.
Number of HLA-B7+ individuals that had a CTL response to this epitope broken down by group: 2/4 group 1, 1/3 group 2, and 1/1 group 3.

References

Displaying record number 1577

HXB2 Location	Nef(13-20) DNA(8833..8856)	Nef Epitope Map
Author Location	Nef(13-20 SF2)
Epitope	`WPTVRERM`	Epitope Alignment
Species (MHC/HLA)	human(B8)
Immunogen	HIV-1 infection
Experimental methods
Keywords	HAART, ART, acute/early infection

Notes

Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in individuals treated during chronic infection.
The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11 individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection (Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef.
Previously described and newly defined optimal epitopes were tested for CTL response.
Number of HLA-B8+ individuals that had a CTL response to this epitope broken down by group: 1/3 group 1, 0/3 group 2, and 1/2 group 3.

References

Displaying record number 1570

HXB2 Location	Nef(68-77) DNA(8998..9027)	Nef Epitope Map
Author Location	Nef(68-77 SF2)
Epitope	`FPVTPQVPLR`	Epitope Alignment
Species (MHC/HLA)	human(B7)
Immunogen	HIV-1 infection
Experimental methods
Keywords	HAART, ART, acute/early infection

Notes

Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in individuals treated during chronic infection.
The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11 individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection (Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef.
Previously described and newly defined optimal epitopes were tested for CTL response.
Number of HLA-B7+ individuals that had a CTL response to this epitope broken down by group: 0/4 group 1, 0/3 group 2, and 1/1 group 3.

References

Displaying record number 1571

HXB2 Location	Nef(71-79) DNA(9007..9033)	Nef Epitope Map
Author Location	Nef(71-79 SF2)
Epitope	`TPQVPLRPM`	Epitope Alignment
Species (MHC/HLA)	human(B7)
Immunogen	HIV-1 infection
Experimental methods
Keywords	HAART, ART, acute/early infection

Notes

Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in individuals treated during chronic infection.
The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11 individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection (Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef.
Previously described and newly defined optimal epitopes were tested for CTL response.
Number of HLA-B7+ individuals that had a CTL response to this epitope broken down by group: 0/4 group 1, 0/3 group 2, and 1/1 group 3.

References

Displaying record number 1527

HXB2 Location	Nef(73-82) DNA(9013..9042)	Nef Epitope Map
Author Location	Nef(73-82 SF2)
Epitope	`QVPLRRMTYK`	Epitope Alignment
Species (MHC/HLA)	human(A3)
Immunogen	HIV-1 infection
Experimental methods
Keywords	HAART, ART, acute/early infection

Notes

Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in individuals treated during chronic infection.
The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11 individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection (Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef.
Previously described and newly defined optimal epitopes were tested for CTL response.
Number of HLA-A3+ individuals that had a CTL response to this epitope broken down by group: 3/7 group 1, 1/4 group 2, and 1/2 group 3.

References

Displaying record number 1572

HXB2 Location	Nef(77-85) DNA(9025..9051)	Nef Epitope Map
Author Location	Nef(77-85 SF2)
Epitope	`RPMTYKAAL`	Epitope Alignment
Species (MHC/HLA)	human(B7)
Immunogen	HIV-1 infection
Experimental methods
Keywords	HAART, ART, acute/early infection

Notes

Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in individuals treated during chronic infection.
The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11 individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection (Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef.
Previously described and newly defined optimal epitopes were tested for CTL response.
Number of HLA-B7+ individuals that had a CTL response to this epitope broken down by group: 1/4 group 1, 0/3 group 2, and 1/1 group 3.

References

Displaying record number 1549

HXB2 Location	Nef(82-91) DNA(9040..9069)	Nef Epitope Map
Author Location	Nef(82-91 SF2)
Epitope	`KAAVDLSHFL`	Epitope Alignment
Species (MHC/HLA)	human(Cw8)
Immunogen	HIV-1 infection
Experimental methods
Keywords	HAART, ART, acute/early infection

Notes

Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in individuals treated during chronic infection.
The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11 individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection (Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef.
Previously described and newly defined optimal epitopes were tested for CTL response.
Number of HLA-Cw8+ individuals that had a CTL response to this epitope broken down by group: 1/3 group 1, 0/0 group 2, and 0/1 group 3.

References

Displaying record number 1542

HXB2 Location	Nef(84-92) DNA(9046..9072)	Nef Epitope Map
Author Location	Nef(84-92 SF2)
Epitope	`AVDLSHFLK`	Epitope Alignment
Species (MHC/HLA)	human(A11)
Immunogen	HIV-1 infection
Experimental methods
Keywords	HAART, ART, acute/early infection

Notes

Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in individuals treated during chronic infection.
The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11 individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection (Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef.
Previously described and newly defined optimal epitopes were tested for CTL response.
Number of HLA-A11+ individuals that had a CTL response to this epitope broken down by group: 0/3 group 1, 0/0 group 2, and 2/2 group 3.

References

Displaying record number 1578

HXB2 Location	Nef(90-97) DNA(9064..9087)	Nef Epitope Map
Author Location	Nef(88-95 SF2)
Epitope	`FLKEKGGL`	Epitope Alignment
Species (MHC/HLA)	human(B8)
Immunogen	HIV-1 infection
Experimental methods
Keywords	HAART, ART, acute/early infection

Notes

Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in individuals treated during chronic infection.
The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11 individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection (Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef.
Previously described and newly defined optimal epitopes were tested for CTL response.
Number of HLA-B8+ individuals that had a CTL response to this epitope broken down by group: 3/3 group 1, 1/3 group 2, and 1/2 group 3.

References

Displaying record number 1528

HXB2 Location	Nef(92-100) DNA(9070..9096)	Nef Epitope Map
Author Location	Nef(90-98 SF2)
Epitope	`KEKGGLEGL`	Epitope Alignment
Species (MHC/HLA)	human(B60)
Immunogen	HIV-1 infection
Experimental methods
Keywords	HAART, ART, acute/early infection

Notes

Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in individuals treated during chronic infection.
The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11 individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection (Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef.
Previously described and newly defined optimal epitopes were tested for CTL response.
Number of HLA-B60+ individuals that had a CTL response to this epitope broken down by group: 2/2 group 1, 1/1 group 2, and 0/0 group 3.

References

Displaying record number 1566

HXB2 Location	Nef(105-114) DNA(9109..9138)	Nef Epitope Map
Author Location	Nef(105-114 SF2)
Epitope	`RRQDILDLWI`	Epitope Alignment
Species (MHC/HLA)	human(B27)
Immunogen	HIV-1 infection
Experimental methods
Keywords	HAART, ART, acute/early infection

Notes

Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in individuals treated during chronic infection.
The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11 individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection (Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef.
Previously described and newly defined optimal epitopes were tested for CTL response.
Number of HLA-B27+ individuals that had a CTL response to this epitope broken down by group: 0/0 group 1, 0/0 group 2, and 1/1 group 3.

References

Displaying record number 1529

HXB2 Location	Nef(120-128) DNA(9154..9180)	Nef Epitope Map
Author Location	Nef(118-126 SF2)
Epitope	`YFPDWQNYT`	Epitope Alignment
Species (MHC/HLA)	human(A1)
Immunogen	HIV-1 infection
Experimental methods
Keywords	HAART, ART, acute/early infection

Notes

Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in individuals treated during chronic infection.
The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11 individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection (Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef.
Previously described and newly defined optimal epitopes were tested for CTL response.
Number of HLA-A1+ individuals that had a CTL response to this epitope broken down by group: 0/3 group 1, 0/2 group 2, and 1/2 group 3.

References

Displaying record number 1573

HXB2 Location	Nef(128-137) DNA(9178..9207)	Nef Epitope Map
Author Location	Nef(128-137 SF2)
Epitope	`TPGPGVRYPL`	Epitope Alignment
Species (MHC/HLA)	human(B7)
Immunogen	HIV-1 infection
Experimental methods
Keywords	HAART, ART, acute/early infection

Notes

Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in individuals treated during chronic infection.
The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11 individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection (Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef.
Previously described and newly defined optimal epitopes were tested for CTL response.
Number of HLA-B7+ individuals that had a CTL response to this epitope broken down by group: 0/4 group 1, 0/3 group 2, and 1/1 group 3.

References

Displaying record number 1543

HXB2 Location	Nef(134-141) DNA(9196..9219)	Nef Epitope Map
Author Location	Nef(138-147 SF2)
Epitope	`RYPLTFGW`	Epitope Alignment
Species (MHC/HLA)	human(A24)
Immunogen	HIV-1 infection
Experimental methods
Keywords	HAART, ART, acute/early infection

Notes

Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in individuals treated during chronic infection.
The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11 individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection (Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef.
Previously described and newly defined optimal epitopes were tested for CTL response.
Number of HLA-A24+ individuals that had a CTL response to this epitope broken down by group: 0/0 group 1, 2/3 group 2, and 0/0 group 3.

References

Displaying record number 1568

HXB2 Location	Nef(135-143) DNA(9199..9225)	Nef Epitope Map
Author Location	Nef(135-143 SF2)
Epitope	`YPLTFGWCY`	Epitope Alignment
Species (MHC/HLA)	human(B18)
Immunogen	HIV-1 infection
Experimental methods
Keywords	HAART, ART, acute/early infection

Notes

Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in individuals treated during chronic infection.
The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11 individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection (Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef.
Previously described and newly defined optimal epitopes were tested for CTL response.
Number of HLA-B18+ individuals that had a CTL response to this epitope broken down by group: 0/3 group 1, 1/2 group 2, and 0/0 group 3.

References

Displaying record number 1558

HXB2 Location	Nef(166-177) DNA(9292..9327)	Nef Epitope Map
Author Location	Nef(160-179 SF2)
Epitope	`HPVSLHGMDDPE`	Epitope Alignment
Species (MHC/HLA)	human(B35)
Immunogen	HIV-1 infection
Experimental methods
Keywords	HAART, ART, acute/early infection

Notes

Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in individuals treated during chronic infection.
The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11 individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection (Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef.
Previously described and newly defined optimal epitopes were tested for CTL response.
Number of HLA-B35+ individuals that had a CTL response to this epitope broken down by group: 1/2 group 1, 0/2 group 2, and 0/1 group 3.

References

Displaying record number 1531

HXB2 Location	Nef(190-198) DNA(9364..9390)	Nef Epitope Map
Author Location	Nef(190-198 SF2)
Epitope	`AFHHVAREL`	Epitope Alignment
Species (MHC/HLA)	human(A2)
Immunogen	HIV-1 infection
Experimental methods
Keywords	HAART, ART, acute/early infection

Notes

Therapy provided during acute infection resulted in a narrower CTL response, stronger T help response, and a less diverse viral population than was seen in individuals treated during chronic infection.
The breadth and specificity of the response was determined using ELISPOT by studying 19 individuals with pre-seroconversion therapy (Group 1), 11 individuals with primary infection but post-seroconversion therapy (Group 2), and 10 individuals who responded to HAART given during chronic infection (Group 3), using 259 overlapping peptides spanning p17, p24, RT, gp41, gp120 and Nef.
Previously described and newly defined optimal epitopes were tested for CTL response.
Number of HLA-A2+ individuals that had a CTL response to this epitope broken down by group: 0/10 group 1, 1/6 group 2, and 0/4 group 3.